[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-b-virus---chronic-active\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-b-virus---chronic-active":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100470223",false,"NCT05403047","Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women","Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women Infected With Hepatitis B Virus (HBeAg Positive or With a High Viral Load) and Whose Newborns Had Been Vaccinated at Birth","TOPCHIB","Inclusion criteria:\n\n* Pregnant women with a term of less than 24 weeks of amenorrhea;\n* HBsAg positive ;\n* HBeAg positive or HBeAg negative with a high viral load ( \\> 200 000 UI\u002Fml) ;\n* 16 years old or more on the inclusion day ;\n* Signature of free and informed consent (for pregnant women aged 16 to 21, the participant's consent as well as the authorization of a parent\u002Fadult husband\u002F legal tutor will be collected) which also includes consent for the children\n\nExclusion criteria :\n\n* HIV co-infection;\n* Women treated for HBV;\n* Creatinine clearance \\\u003C30 ml \u002F min;\n* Suspicion of poor monitoring of children's vaccination schedule for HBV (vaccination at birth + boosters);\n* Disease or treatment contraindicating the taking of TDF.","FEMALE","16 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and followed by three booster doses, according to the Expanded Programme on Immunisation.\n\nThe investigators hypothesise that a short course of TDF could greatly reduce the risk of HBV MTCT in pregnant women at high risk of MTCT (HBeAg positive or with high viral load).",[26],"Hepatitis B Virus - Chronic Active","RECRUITING","2026-06-25",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2023-08-22",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"ANRS, Emerging Infectious Diseases","OTHER_GOV",""]